<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PRIMAQUINE PHOSPHATE</span><br/>(prim'a-kween)<br/><span class="topboxtradename">Primaquine<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antimalarial</span><br/><b>Prototype: </b>Chloroquine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>26.3 mg tablets; 5 g, 25 g, 100 g, 500 g powder</p>
<h1><a name="action">Actions</a></h1>
<p>Acts on primary exoerythrocytic forms of <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> by an incompletely known mechanism. Destroys late tissue forms of <i>P. vivax</i> and thus effects radical cure (prevents relapse).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Gametocidal activity against all species of plasmodia that infect man; interrupts transmission of malaria.</p>
<h1><a name="uses">Uses</a></h1>
<p>To prevent relapse ("radical" or "clinical" cure) of <i>P. vivax</i> and <i>P. ovale</i> malarias and to prevent attacks after departure from areas where <i>P. vivax</i> and <i>P. ovale</i> malarias are endemic. With clindamycin for the treatment of <i>Pneumocystis carinii</i> pneumonia (PCP) in AIDS.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Rheumatoid arthritis; lupus erythematosus (SLE); hemolytic drugs, concomitant or recent use of agents capable of bone marrow
         depression (e.g., quinacrine; patients with G6PD deficiency). NADH methemoglobin reductase deficiency; pregnancy (category
         C), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Malaria Relapse Prevention</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg once/d for 14 d concomitantly or consecutively with  chloroquine or hydroxychloroquine on first 3 d of acute attack<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.3 mg/kg once/d for 14 d concomitantly or consecutively with chloroquine or hydroxychloroquine on first 3 d of acute attack<br/><br/><span class="indicationtitle">Malaria Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg once/d for 14 d beginning immediately after leaving malarious area<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.3 mg/kg once/d for 14 d beginning immediately after leaving malarious area<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug at mealtime or with an antacid (prescribed); may prevent or relieve gastric irritation. Notify physician if GI symptoms
            persist.
         </li>
<li>Store in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span> <span class="speceff-life">Hematologic reactions including granulocytopenia and acute hemolytic anemia in patients with G6PD deficiency</span>, moderate leukocytosis or leukopenia, anemia, granulocytopenia, agranulocytosis. <span class="typehead">GI:</span> Nausea, vomiting, epigastric distress, abdominal cramps. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Metabolic:</span> Methemoglobinemia (cyanosis). <span class="typehead">Body as a Whole:</span> Headache, confusion, mental depression. <span class="typehead">Special Senses:</span> Disturbances of visual accommodation. <span class="typehead">CV:</span> Hypertension, arrhythmias (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Toxicity of both <b>quinacrine</b> and primaquine increased. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 6 h. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver to active metabolites. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 3.79.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be aware drug may precipitate acute hemolytic anemia in patients with G6PD deficiency, an inherited error of metabolism carried
            on the X chromosome, present in about 10% of American black males and certain white ethnic groups: Sardinians, Sephardic
            Jews, Greeks, and Iranians. Whites manifest more intense expression of hemolytic reaction than do blacks. Screen for prior
            to initiation of therapy.
         </li>
<li>Lab tests: Perform repeated hematologic studies (particularly blood cell counts and Hgb) and urinalyses during therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Examine urine after each voiding and to report to physician darkening of urine, red-tinged urine, and decrease in urine volume.
            Also report chills, fever, precordial pain, cyanosis (all suggest a hemolytic reaction). Sudden reductions in hemoglobin or
            erythrocyte count suggest an impending hemolytic reaction.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>